Investigation of genes and pathways involved in breast cancer subtypes through gene expression meta-analysis
- PMID: 35181505
- DOI: 10.1016/j.gene.2022.146328
Investigation of genes and pathways involved in breast cancer subtypes through gene expression meta-analysis
Abstract
Background: Molecular-based studies have revealed heterogeneity in Breast cancer BC while also improving classification and treatment. However, efforts are underway to distinguish between distinct subtypes of breast cancer. In this study, the results of several microarray studies were combined to identify genes and pathways specific to each BC subtype.
Methods: Meta-analysis of multiple gene expression profile datasets was screened to find differentially expressed genes (DEGs) across subtypes of BC and normal breast tissue samples. Protein-protein interaction network and gene set enrichment analysis were used to identify critical genes and pathways associated with BC subtypes. The differentially expressed genes from meta-analysis was validated using an independent comprehensive breast cancer RNA-sequencing dataset obtained from the Cancer Genome Atlas (TCGA).
Results: We identified 110 DEGs (13 DEGs in all and 97 DEGs in each subtype) across subtypes of BC. All subtypes had a small set of shared DEGs enriched in the Chemokine receptor bind chemokine pathway. Luminal A specific were enriched in the translational elongation process in mitochondria, and the enhanced process in luminal B subtypes was interferon-alpha/beta signaling. Cell cycle and mitotic DEGs were enriched in the basal-like group. All subtype-specific DEG genes (100%) were successfully validated for Luminal A, Luminal B, ERBB2, and Normal-like. However, the validation percentage for Basal-like group was 77.8%.
Conclusion: Integrating researches such as a meta-analysis of gene expression might be more effective in uncovering subtype-specific DEGs and pathways than a single-study analysis. It would be more beneficial to increase the number of studies that use matched BC subtypes along with GEO profiling approaches to reach a better result regarding DEGs and reduce probable biases. However, achieving 77.8% overlap in basal-specific genes and complete concordance in specific genes related to other subtypes can implicate the strength of our analysis for discovering the subtype-specific genes.
Keywords: Breast cancer; Breast cancer subtypes; Gene expression meta-analysis; Microarray.
Copyright © 2022 Elsevier B.V. All rights reserved.
Similar articles
-
Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms.BMC Genomics. 2006 May 26;7:127. doi: 10.1186/1471-2164-7-127. BMC Genomics. 2006. PMID: 16729877 Free PMC article.
-
Identification of collaboration patterns of dysfunctional pathways in breast cancer.Int J Clin Exp Pathol. 2014 Jun 15;7(7):3853-64. eCollection 2014. Int J Clin Exp Pathol. 2014. PMID: 25120762 Free PMC article.
-
Screening of differentially expressed genes and identification of NUF2 as a prognostic marker in breast cancer.Int J Mol Med. 2019 Aug;44(2):390-404. doi: 10.3892/ijmm.2019.4239. Epub 2019 Jun 11. Int J Mol Med. 2019. PMID: 31198978 Free PMC article.
-
Molecular Profiles of Breast Cancer in Hispanic/Latina.2019 Dec 13. In: Ramirez AG, Trapido EJ, editors. Advancing the Science of Cancer in Latinos [Internet]. Cham (CH): Springer; 2020. Chapter 10. 2019 Dec 13. In: Ramirez AG, Trapido EJ, editors. Advancing the Science of Cancer in Latinos [Internet]. Cham (CH): Springer; 2020. Chapter 10. PMID: 34460196 Free Books & Documents. Review.
-
Molecular subtyping of breast cancer: opportunities for new therapeutic approaches.Cell Mol Life Sci. 2007 Dec;64(24):3219-32. doi: 10.1007/s00018-007-7389-z. Cell Mol Life Sci. 2007. PMID: 17957336 Free PMC article. Review.
Cited by
-
Expression pattern of non-coding RNAs in non-functioning pituitary adenoma.Front Oncol. 2022 Sep 2;12:978016. doi: 10.3389/fonc.2022.978016. eCollection 2022. Front Oncol. 2022. PMID: 36119500 Free PMC article.
-
Pan-Cancer Screening and Validation of CALU's Role in EMT Regulation and Tumor Microenvironment in Triple-Negative Breast Cancer.J Inflamm Res. 2024 Sep 25;17:6743-6764. doi: 10.2147/JIR.S477846. eCollection 2024. J Inflamm Res. 2024. PMID: 39345892 Free PMC article.
-
Evaluation of lncRNAs as Potential Biomarkers for Diagnosis of Metastatic Triple-Negative Breast Cancer through Bioinformatics and Machine Learning.Iran J Biotechnol. 2024 Jul 1;22(3):e3853. doi: 10.30498/ijb.2024.432171.3853. eCollection 2024 Jul. Iran J Biotechnol. 2024. PMID: 39737204 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous